Brighten Optix Corporation (TPEX:6747)

Market Cap	5.32B
Revenue (ttm)	778.00M
Net Income (ttm)	61.62M
Shares Out	27.20M
EPS (ttm)	2.25
PE Ratio	87.08
Forward PE	n/a
Dividend	9.19 (4.70%)
Ex-Dividend Date	Apr 17, 2025

Volume	38,398
Average Volume	37,161
Open	194.50
Previous Close	194.00
Day's Range	194.50 - 195.50
52-Week Range	124.00 - 195.50
Beta	0.17
RSI	79.58
Earnings Date	Aug 12, 2025

About Brighten Optix

Brighten Optix Corporation researches, develops, manufactures, and sells contact lenses in Taiwan and internationally. The company offers orthokeratology, a non-invasive and reversible method of vision correction by using a hard contact lens to alter the shape of the front surface of the cornea; gas permeable lenses for single vison, multifocal, and irregular cornea and keratoconus correction, under the HiClear, So2clear, Menicon, Duette, ROSE K, Ampleye, MAXIM 3D, AND ULTRAHEALTH brand name; and soft contact lenses under the iDealsoft, Briomoi...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1965
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6747

Financial Performance

In 2024, Brighten Optix's revenue was 766.93 million, an increase of 2.63% compared to the previous year's 747.30 million. Earnings were 149.79 million, a decrease of -24.82%.